On the occasion of the visit of Dutch Prime Minister Mark Rutte to India, the two countries have decided to expand their existing cooperation in the area of large scale cohort studies with a Joint Cohort study on HIV patients in India.
Cluster Development Programme for Pharma Sector (CDS-PS) is launched by Government to provide support to the Pharmaceutical industry in becoming more capable, productive and competitive. End of this financial year, 06 Pharma Clusters are likely to come up of which 03 will be greenfields.
Under “Make in India” initiative India and the Netherlands have signed a Memorandum of Understanding for the development of vaccines. The MoU was signed between visiting Prime Minister of Netherlands Mark Rutte and government of India in New Delhi. This cooperation between the two countries in the vaccine manufacturing segment is expected to result in large scale production of measles-rubella and other needed vaccine in the country. The ‘Make in India’ is a critical initiative for promoting access to health technology beyond the borders of India.
The Indian Council on Medical Research (ICMR) and the National Institutes of Health (NIH), US, will soon begin collaborative research on ‘Prevention of Sexually Transmitted Diseases & HIV/AIDS’. The joint research programme will also have thrust on HIV and AIDS-associated co-morbidities. Under this, the focus will be on utilsation of new/enhanced therapeutics for HIV-related co-morbidities such as HCV and their impact on disease outcomes; and enhanced targeted outreach strategies for HCV testing, prevention, and treatment/care engagement; integrated approaches for addressing the complex bio-behavioral factors associated with HCV/HIV. In this regard a joint Indo-US workshop is proposed to be held in September 2015 to encourage investigators for the Indo-US collaborative projects. Under translational research, the focus will be on studies to develop and test innovative HIV prevention strategies in young populations, particularly adolescents; and also on studies to better understand linkages between reproductive health options and HIV infection in men and women.
(NewsVoir); With Indian pharmaceutical exports to the United States and other markets showing a marked increase over the last year, government regulatory agencies have started emphasizing the need to ensure consistent quality of drugs manufactured in India. The drugs standardization compliance and regulatory requirements need to be at par with the international regulations, including the US FDA, allowing drug manufacturers to maintain competitive advantage.
A team of researchers from CSIR-CIMAP (Council of Scientific and Industrial Research-Central Institute of Medical & Aromatic Plants) in Lucknow have successfully completed the genome sequencing of Tulsi (Basil) plant and very soon are expected to unravel the therapeutic secrets of its medical properties. This is the first report of complete genome sequence of a traditional and most respected medicinal plant of India, using a composite next generation sequencing technologies.
Drugs Controller General India (DCGI) has issued a notice in observance of the compliance for patient safety which seems more appealing and beneficial. DCGI notified to drug importers that they will inform or report to Indian authorities about time to time regulatory actions taken on their drugs in different countries where drugs are sold or distributed.
National Pharmaceutical Pricing Authority (NPPA) given a final opportunity to companies to register with Integrated Pharmaceutical Database Management System (IPDMS). 19 companies out of Top 100, which have not yet registered with IPDMS as on 01.06.2015.
Around 11 per cent of the people in Delhi are suffering from asthma the government said while attributing its causes to smoking and air pollution.
The Indian Council of Medical Research (ICMR) will soon start research on stillbirth to identify and understand the local causes and risk factors from the medical and sociological perspective. ICMR's initiative on stillbirth is significant as nearly 3 million third-trimester stillbirths occurring worldwide each year and 98 per cent of these occur in low-income and middle-income countries. More than 1 million stillbirths occur in the intrapartum period, which can largely be prevented. The cause of stillbirth remains unidentified in India.